Spaulding Clinical Research, the US-based provider of clinical pharmacology and cardiac core-laboratory services, has announced its second international partnership this month to broaden and globalise its research services offering.
This time Spaulding has teamed up with Clinigene International Limited, part of the Biocon healthcare group and based in Bangalore, India. Clinigene is a Phase I-IV clinical research organisation with central and bioanalytical laboratory capacity.
Earlier this month, the US company announced a transatlantic partnership with France’s Eurofins Optimed Clinical Research to support global studies by pharmaceutical and biotechnology companies.
The strategic partnership with Clinigene International establishes a “reliable, trustworthy, and cost-efficient global footprint for clinical pharmacology services”, giving both companies an opportunity to “engage pharmaceutical clients strategically and accelerate first-in-human to proof-of-concept clinical development”, Spaulding said.
Complementary strengths
Randol Spaulding, chief executive officer (CEO) of Spaulding Clinical, described the new partners’ strengths as highly complementary.
While Clinigene can offer preclinical development services through its sister-company Syngene, Spaulding will cover the FIH/SAD/MAD (first in human/ single ascending dose/multiple ascending dose) end.
Clinigene also provides DDI (drug-drug interaction) and proof-of-concept services, backed up by its central and bioanalytical laboratories.
“With Clinigene’s expertise and cost-effective approach to BA/BE [bioavailability.bioequivalence] and Spaulding’s market-leading TQT [cardiac risk] study and Cardiac Core Lab expertise, our clients are able to easily structure a programme for their compound that delivers high-value while keeping the molecule knowledge experts involved throughout the entire early clinical development of the compound,” the CEO added.
